9 0 8 0 2
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 2.6 Breast Cancer (Dove Med Press)
- 3.9 Clin Epidemiol
- 3.3 Cancer Manag Res
- 3.9 Infect Drug Resist
- 3.6 Clin Interv Aging
- 4.8 Drug Des Dev Ther
- 2.8 Int J Chronic Obstr
- 8.0 Int J Nanomed
- 2.3 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 4.0 OncoTargets Ther
- 2.2 Patient Prefer Adher
- 2.8 Ther Clin Risk Manag
- 2.7 J Pain Res
- 3.3 Diabet Metab Synd Ob
- 4.3 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.9 Pharmgenomics Pers Med
- 3.5 Risk Manag Healthc Policy
- 4.5 J Inflamm Res
- 2.3 Int J Gen Med
- 4.1 J Hepatocell Carcinoma
- 3.2 J Asthma Allergy
- 2.3 Clin Cosmet Investig Dermatol
- 3.3 J Multidiscip Healthc
已发表论文
甲状腺转录因子 1 的表达与中国肺腺癌患者的表皮生长因子受体基因的外显子 21 突变有显著关联
Authors Zhao QC, Xu S, Liu JH, Li Y, Fan YG, Shi T, Wei S, Tang SC, Liu HY, Chen J
Received 16 June 2015
Accepted for publication 7 August 2015
Published 7 September 2015 Volume 2015:8 Pages 2469—2478
DOI http://dx.doi.org/10.2147/OTT.S90602
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Jing Zhang
Peer reviewer comments 3
Editor who approved publication: Professor Jianmin Xu
Objective: The aim of this retrospective study was to investigate the relationship between thyroid transcription factor-1 (TTF-1) expression and epidermal growth factor receptor (EGFR ) gene mutations in lung adenocarcinomas of Chinese patients.
Methods: There were 200 lung adenocarcinoma patients who were enrolled in this study. Tumor specimens of these patients were investigated for TTF-1 expression and mutations in EGFR using immunohistochemistry and a liquid chip platform for DNA analysis of slides with sections of formalin-fixed, paraffin-embedded specimens.
Results: The rates of TTF-1 expression and EGFR mutations were 81.5% and 45.5%, respectively, in the lung adenocarcinoma specimens of the recruited patients. Among female nonsmokers (n=72), 93.1% of specimens were positive for TTF-1 expression, and 63.9% had EGFR mutations. Of 89 patients with EGFR mutations, 83 (50.9%) specimens were simultaneously positive for TTF-1 expression. Kaplan–Meier analysis of all patient specimens found that postoperative survival time was not significantly associated with TTF-1 expression and the presence of EGFR mutations. However, patients with disease stages III–IV whose tumors were positive for TTF-1 expression and EGFR mutations had better postoperative survival than similar patients whose tumors were negative for TTF-1 expression and EGFR mutations.
Conclusion: Our study showed a significant association between TTF-1 positivity and the presence of EGFR mutations (exon 21) in the Chinese lung adenocarcinoma patients. We further identify that patients with disease stages III–IV who were positive for TTF-1 expression and EGFR mutations had a better postoperative survival than those patients who were negative for TTF-1 expression and EGFR mutations. Therefore, TTF-1 might be a potential prognostic biomarker for stages III–IV lung adenocarcinoma patients. In clinical practice, TTF-1 expression may be a marker for planning therapy for certain patients with lung adenocarcinoma, especially for selection of EGFR tyrosine kinase inhibitors.
Keywords: EGFR , lung adenocarcinoma, survival, TTF-1
Methods: There were 200 lung adenocarcinoma patients who were enrolled in this study. Tumor specimens of these patients were investigated for TTF-1 expression and mutations in EGFR using immunohistochemistry and a liquid chip platform for DNA analysis of slides with sections of formalin-fixed, paraffin-embedded specimens.
Results: The rates of TTF-1 expression and EGFR mutations were 81.5% and 45.5%, respectively, in the lung adenocarcinoma specimens of the recruited patients. Among female nonsmokers (n=72), 93.1% of specimens were positive for TTF-1 expression, and 63.9% had EGFR mutations. Of 89 patients with EGFR mutations, 83 (50.9%) specimens were simultaneously positive for TTF-1 expression. Kaplan–Meier analysis of all patient specimens found that postoperative survival time was not significantly associated with TTF-1 expression and the presence of EGFR mutations. However, patients with disease stages III–IV whose tumors were positive for TTF-1 expression and EGFR mutations had better postoperative survival than similar patients whose tumors were negative for TTF-1 expression and EGFR mutations.
Conclusion: Our study showed a significant association between TTF-1 positivity and the presence of EGFR mutations (exon 21) in the Chinese lung adenocarcinoma patients. We further identify that patients with disease stages III–IV who were positive for TTF-1 expression and EGFR mutations had a better postoperative survival than those patients who were negative for TTF-1 expression and EGFR mutations. Therefore, TTF-1 might be a potential prognostic biomarker for stages III–IV lung adenocarcinoma patients. In clinical practice, TTF-1 expression may be a marker for planning therapy for certain patients with lung adenocarcinoma, especially for selection of EGFR tyrosine kinase inhibitors.
Keywords: EGFR , lung adenocarcinoma, survival, TTF-1
